Feeds:
Posts
Comments

Archive for the ‘Diagnosis’ Category

PROSTABLOG NZ: I seem to be hearing from more and more friends and acquaintances that they’ve got prostate cancer.

And it’s not because they know I do this blog. These are people who’ve never read it. Why would they? Who would – until they are diagnosed, of course.

It’s difficult to know what to say to people who contact me. I never give medical advice (I’m not a doctor, after all), but I can tell people where to look for information. I guess that’s something.

It makes me think I should have another close look at current web postings on prostate cancer and update things.

Watch for new postings over the next few weeks.

Read Full Post »

SCIENCE DAILY: The size and shape of the blood vessels visible within a prostate cancer tumour may be a useful clue to how the cancer will behave and how it needs to be treated. READ MORE>

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumour will behave.

Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

The answer may lie in the size and shape of the blood vessels that are visible within the cancer.

Read Full Post »

URO TODAY: Giving newly diagnosed prostate cancer patients a bone scan has dropped off dramatically since the advent of PSA tests, but new research suggests reading PSA levels and Gleason score can accurately predict when bone scans are needed. READ MORE>

The combination of Gleason score and PSA enhances predictability of bone scans in newly diagnosed prostate cancer patients.

The PSA threshold for ordering bone scans should be adjusted according to Gleason score. For patients with Gleason scores less than 7, we recommend a bone scan if the PSA is higher than 30 ng/ml.

However, for patients with a high Gleason score (8-10), we recommend a bone scan if the PSA is higher than 10 ng/ml.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: The classification system used for prostate tumours within the gland may not be as much use in predicting the risk of cancer progressing as originally thought. “Current pT2 prostate cancer sub-stages may not have prognostic significance for intermediate term outcomes,” say researchers. READ MORE>

There are three pathological sub-classifications of prostate cancer that is confined to the prostate: T2a disease (cancer confined to one half of either the left or right lobe or side of the prostate), T2b disease (cancer that is found throughout one lobe or side of the prostate) and T2c disease (cancer that is evident in both lobes or sides of the prostate).

Read Full Post »

URO TODAY: The risk of prostate cancer can be estimated in individual men primarily using PSA, but also prostate volume, previous biopsy status, family history and ethnicity. READ MORE>

Men at increased risk warrant enhanced surveillance and in the future may also be candidates for active risk reduction strategies.

Read Full Post »

URO TODAY: Medical professionals should pay more attention to the emotional burden felt by prostate cancer patients, because their stress and strains during the time before treatment have a rather more emotional than physical character. READ MORE>

Read Full Post »

URO TODAY: Not all patients with a biopsy prostate cancer Gleason score of  6 (< /=3 + 3) – usually considered safe – have low-risk disease, according to new German research. READ MORE>

High-risk Gleason score < /=3 + 3 patients have a similar risk profile as more favourable GS 3 + 4 patients. This finding warrants consideration when deciding on treatment.

Read Full Post »

« Newer Posts - Older Posts »